alexa

GET THE APP

Acute Lymphoblastic Leukemia (ALL) And Proteomics: Looking For Protein-biomarkers Of Pediatric Relapses | 17618
ISSN: 2329-6879

Occupational Medicine & Health Affairs
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Acute lymphoblastic leukemia (ALL) and proteomics: Looking for protein-biomarkers of pediatric relapses

3rd International Conference and Exhibition on Occupational Health & Safety

Elena L?pez

Accepted Abstracts: Occup Med Health Aff

DOI: 10.4172/2329-6879.S1.020

Abstract
It may be a clich?, but it is nonetheless true: if we all have achieved more, it is because we stand on the shoulders of those early giants. Because of them, the cure of childhood ALL may be the greatest cancer story ever told (By Joseph V. Simone, MD: December 2008 as part of the special ASH anniversary brochure, 50 Years in Hematology: Research that revolutionized patient care. Since 1950, important break throughs in the treatment of pediatric ALL have been achieved. Now a days, more than 80% of children suffering ALL can be cured. However, around 30% of the patients will still relapse, being this group of patients the ones focused by the investigators. We aim to review proteomics research on pediatric ALL due to (a) this tool is providing several important advances to combat cancer cells, (b) when applying phosphoproteomics for leukemia investigation, novel and real protein-biomarkers of resistance or sensitivity to drugs which target the signalling-networks will appear. We detail important tips for a proper phospho-quantitative design and strategy for pediatric ALL (relapse vs. remission) research studies when using human body fluids from cerebrospinal and bone-marrow. A schedule for the analysis of samplesbody fluids according to the different states of the patients is explained. Moreover, important advances on leukemia coupled to proteomics tools are also explained. The final goal is to stimulate pediatric ALL research via proteomics in order to ?build? the reference map of the signalling-networks from leukemic cells at relapse, thus significant clinical and therapy advances for ALL-relapse can be achieved.
Biography
Relevant Topics
Top